布地奈德福莫特罗联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠综合征的临床效果研究  

Clinical study of budesonide/formoterol combined with tiotropium bromide in the treatment of asthma chronic obstructive pulmonary disease overlap syndrome

作　　者：甘建国 GAN Jian-guo(Third Department of Internal Medicine,Chongyi County People's Hospital,Ganzhou 341300,China)

机构地区：[1]江西省崇义县人民医院内三科,341300

出　　处：《中国实用医药》2025年第5期95-98,共4页China Practical Medicine

摘　　要：目的分析哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)患者接受布地奈德福莫特罗联合噻托溴铵进行治疗的效果。方法68例ACOS患者,根据治疗方法的不同分为对照组和实验组,每组34例。对照组应用布地奈德福莫特罗进行治疗,实验组在对照组基础上联合噻托溴铵进行治疗。对比两组治疗效果、病情转归情况[哮喘控制测试(ACT)、慢性阻塞性肺疾病评估测试(CAT)评分]、肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC]及炎症因子[白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)]水平、不良反应发生率。结果实验组患者治疗总有效率97.06%较对照组的76.47%更高(P<0.05)。治疗后,实验组CAT评分(15.52±5.16)分较对照组的(21.35±5.21)分低,ACT评分(23.33±4.14)分较对照组的(18.24±4.19)分高(P<0.05)。治疗后,实验组FEV1(2.69±0.59)L、FVC(2.79±0.23)L、FEV1/FVC(69.33±3.69)%均较对照组的(1.81±0.33)L、(2.51±0.18)L、(61.25±3.27)%明显上升(P<0.05)。治疗后,实验组IL-6(16.16±3.86)ng/L、hs-CRP(7.24±1.02)mg/L及TNF-α(17.11±4.33)μg/L均较对照组的(20.97±4.11)ng/L、(9.34±1.56)mg/L、(21.24±4.25)μg/L明显下降(P<0.05)。实验组不良反应发生率5.88%较对照组的29.41%低(χ^(2)=6.476,P=0.011<0.05)。结论布地奈德福莫特罗+噻托溴铵治疗方案对于改善ACOS患者肺功能、缓解患者临床症状、减轻炎症反应有显著治疗效果,且不良反应较少,具有一定的安全性。Objective To analyze the effect of budesonide/formoterol combined with tiotropium bromide in the treatment of asthma chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods 68 patients with ACOS were divided into control group and experimental group according to different treatment methods,with 34 patients in each group.The control group was treated with budesonide/formoterol,and the experimental group was treated with tiotropium bromide on the basis of the control group.Comparison was made on therapeutic effect,disease outcome[asthma control test(ACT),chronic obstructive pulmonary disease assessment test(CAT)score],pulmonary function index[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC]and inflammatory factors[interleukin-6(IL-6),hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)],and incidence of adverse reactions between the two groups.Results The total effective rate of 97.06%in the experimental group was higher than 76.47%in the control group(P<0.05).After treatment,the experimental group had a lower CAT score of(15.52±5.16)points than(21.35±5.21)points in the control group,and a higher ACT score of(23.33±4.14)points than(18.24±4.19)points in the control group(P<0.05).After treatment,the experimental group had FEV1 of(2.69±0.59)L,FVC of(2.79±0.23)L and FEV1/FVC of(69.33±3.69)%,which were significantly increased compared with(1.81±0.33)L,(2.51±0.18)L and(61.25±3.27)%in the control group(P<0.05).After treatment,the experimental group had IL-6 of(16.16±3.86)ng/L,hs-CRP of(7.24±1.02)mg/L and TNF-αof(17.11±4.33)μg/L,which were significantly decreased compared with(20.97±4.11)ng/L,(9.34±1.56)mg/L and(21.24±4.25)μg/L in the control group(P<0.05).The incidence of adverse reactions of 5.88%in the experimental group was lower than 29.41%in the control group(χ^(2)=6.476,P=0.011<0.05).Conclusion The therapeutic scheme of budesonide/formoterol+tiotropium bromide has a significant therapeutic effect on improving the lung function,re

关 键 词：布地奈德福莫特罗 噻托溴铵 哮喘 慢性阻塞性肺疾病 重叠综合征 治疗效果 

分 类 号：R56[医药卫生—呼吸系统]